Viatris (MIL:1VTRS) Research & Development : €760 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Viatris Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Viatris's Research & Development for the three months ended in Mar. 2024 was €184 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €760 Mil.

Viatris Research & Development Historical Data

The historical data trend for Viatris's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Research & Development Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

575.91

421.36

602.69

625.12

738.37

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Research & Development	Get a 7-Day Free Trial															170.83	192.26	197.89	185.97	183.72

Viatris Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €760 Mil.

Viatris (MIL:1VTRS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viatris Research & Development Related Terms

Thank you for viewing the detailed overview of Viatris's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (MIL:1VTRS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (MIL:1VTRS) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (MIL:1VTRS) Headlines

No Headlines